{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:34:13Z","timestamp":1769819653055,"version":"3.49.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.lungcan.2015.12.010","type":"journal-article","created":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T12:31:32Z","timestamp":1451478692000},"page":"17-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Crizotinib-induced fatal fulminant liver failure"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4963-4827","authenticated-orcid":false,"given":"Robin M.J.M.","family":"van Geel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen J.M.A.","family":"Hendrikx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelmer E.","family":"Vahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique E.","family":"van Leerdam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daan","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H.M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sjaak A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2015.12.010_bib0005","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/ijc.27711","article-title":"Global estimates of cancer prevalence for 27 sites in the adult population in 2008","volume":"132","author":"Bray","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2015.12.010_bib0010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2015.12.010_bib0015","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrclinonc.2012.43","article-title":"Treating ALK-positive lung cancer\u2014early successes and future challenges","volume":"9","author":"Camidge","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.12.010_bib0020","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2015.12.010_bib0025","unstructured":"FDA, Prescribing information Xalkori\u00ae (crizotinib), (2013)."},{"key":"10.1016\/j.lungcan.2015.12.010_bib0030","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0016-5085(89)90081-4","article-title":"Early indicators of prognosis in fulminant hepatic failure","volume":"97","author":"O\u2019Grady","year":"1989","journal-title":"Gastroenterology."},{"key":"10.1016\/j.lungcan.2015.12.010_bib0035","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK\u2014positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2015.12.010_bib0040","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2015.12.010_bib0045","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.clinre.2012.10.003","article-title":"Crizotinib-induced acute hepatitis: First case with relapse after reintroduction with reduced dose","volume":"37","author":"Ripault","year":"2013","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.lungcan.2015.12.010_bib0050","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/jjco\/hyu086","article-title":"Fulminant Hepatitis Following Crizotinib Administration for ALK-positive Non-small-cell Lung Carcinoma","volume":"44","author":"Sato","year":"2014","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.12.010_bib0055","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2010.31.3197","article-title":"HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer","volume":"29","author":"Spraggs","year":"2011","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950021530129X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950021530129X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T08:55:46Z","timestamp":1537088146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950021530129X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":11,"alternative-id":["S016950021530129X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.12.010","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crizotinib-induced fatal fulminant liver failure","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}